BioNTech and Takara enter license agreement for CAR-T; The FDA has freed another batch of J&J's Covid-19 vaccine
Takara Bio has entered an agreement with BioNTech to license out its RetroNectin platform.
Under the agreement, the German BioNTech will be able to use …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
